diabetestalk.net

Lilly Diabetes Twitter

How Pharma Is Using Twitter To Connect With Patients

How Pharma Is Using Twitter To Connect With Patients

How pharma is using Twitter to connect with patients A closer look at what pharma companies are doing in the Twitterverse. Pharma Twitter is not like your Twitter. Your Twitter probably isn't closely regulated by the FDA. Your Twitter presumably is not monitored by dozens of interest groups with competing agendas. Your Twitter probably existed well before Pharma Twitter, because pharma companies are notoriously slow to take up new technology. Your Twitter probably has a lot more interesting and relevant stuff. But if you are looking for a job or a clinical trial, then pharma's corporate Twitter feeds may be just the place for you. Even with the challenges, pharma has jumped onto the social media platform. According to a list maintained by industry blog Eye on FDA , there were nearly 335 company Twitter accounts as of June 2016. These accounts represent some 69 companies, with several companies having multiple accounts, and 201 are active on a daily basis. For example, Eli Lilly & Co. has 10 accounts, with more than half a dozen in the U.S. alone. Why so many accounts? Most companies have accounts associated with certain divisions such as oncology or animal health, and many even have accounts for different geographical regions or for different purposes such as employee recruitment. Still it's not easy for pharma to use Twitter. If a company is going to tweet about a drug, FDA regulations require the company to include the product name, indication, its most pressing risks and a link to an explanation of risks all in the 140-character confines. For this reason, many companies shy away from product promotion on the platform. Here's a closer look at some of the best-known pharma names on Twitter: The British pharma's first Twitter account, @AstraZenecaUS, has less than half Continue reading >>

Bernie Sanders Tweets About Price Of Eli Lilly Drug Send Stock Pricetumbling

Bernie Sanders Tweets About Price Of Eli Lilly Drug Send Stock Pricetumbling

Bernie Sanders tweets about price of Eli Lilly drug send stock pricetumbling Posted 10:42 AM, November 3, 2016, by FOX59 Web , Updated at 11:17AM, November 3, 2016 This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Bernie Sanders tweets about price of Eli Lilly drug send stock pricetumbling INDIANAPOLIS, Ind. How much power is there in a tweet? We may have an answer to that question, at least in one case. Sen. Bernie Sanders Twitter account sent a series of tweets this week aimed at Eli Lilly and its insulin drug, Humalog. The former presidential candidate first tweeted out a link to a Washington Post story about the drug; the newspaper reported that the price has risen from $21 a vial to $250 a vial during the last 20 years. Sanders tweet linking that article went to 2.7 million Twitter followers on his account. But Sanders wasnt finished quite yet, sending several more tweets about the price increase and deriding the greed of the drug industry. What you have is an incredibly powerful and greedy industry charging whatever price they want. Bernie Sanders (@SenSanders) November 1, 2016 Why has the price of Humalog insulin gone up 700% in 20 years? It's simple. The drug industry's greed. pic.twitter.com/SUeSbsr2Ka Bernie Sanders (@SenSanders) November 1, 2016 It makes no sense that the same drug that costs $70 in France costs $450 in the US. We should reduce barriers to importation of drugs. pic.twitter.com/h3MzOSCI7g Bernie Sanders (@SenSanders) November 1, 2016 In the richest nation in the world, diabetes patients are being forced to decide between eating and paying for the drugs they need. pic.twitter.com/Mnq4NSgiPz Bernie Sanders (@SenSanders) November 1, 2016 Eli Continue reading >>

Join Ryan Reed For The Lilly Diabetes #driveyourhealth Track Walk

Join Ryan Reed For The Lilly Diabetes #driveyourhealth Track Walk

Join Ryan Reed for the Lilly Diabetes #DriveYourHealth Track Walk CONCORD, N.C. (May 24, 2017) Grab your friends and family and join Roush Fenway Racing driver Ryan Reed at the Lilly Diabetes #DriveYourHealth Track Walk on Friday, May 26th from 2-4 PM. Get an up-close look at Charlotte Motor Speedway while you walk the 1.5-mile track and help raise money for the Charlotte Chapter of the American Diabetes Association. Im excited for everyone to be able to come out to Charlotte and join me for a lap around the track, said Reed. Getting a look at the banking and making a lap around the 1.5-mile track is a great way to #DriveYourHealth, while also raising money for a great cause and something that I know firsthand can affect so many people. Register here to join Ryan on the walk: For every person who reaches the finish line, Lilly Diabetes will make a donation to the American Diabetes Association Charlotte Chapter. In addition to the donation, participants will get to sign the hood and deck lid of the No. 16 Lilly Diabetes #DriveYourHealth Ford Mustang that will run at Texas in November. For those unable to make it to Charlotte Motor Speedway to participate in the walk, you can still commit to your health. Walk the 1.5 miles at home, join us live on Facebook at 2:00 p.m. EST on Friday, May 26 and tell us how you #DriveYourHealth. Lilly has been a global leader in diabetes care since 1923, when we introduced the worlds first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a wide range of therapies and a continued determination to provide real solutionsfrom medicines to support programs and morewe strive to make life better for all those Continue reading >>

Livongo And Lilly Collaborate On Real-world Diabetes Research

Livongo And Lilly Collaborate On Real-world Diabetes Research

Livongo and Lilly Collaborate on Real-World Diabetes Research Companies join forces to advance predictive and prescriptive recommendations for people with diabetes INDIANAPOLIS and MOUNTAIN VIEW, CA, January 8, 2018 Eli Lilly and Company (NYSE: LLY) and Livongo Health, a leading consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives, today announced a strategic collaboration to study real-world evidence and develop new insights to reduce the burden on people living with diabetes. The research collaboration will combine real-world behavioral studies and claims data to advance knowledge about effective interventions in diabetes care. The companies aim to contribute to medical literature in three areas: Measure the impact of remote diabetes self-management education and support on clinical and healthcare cost outcomes Understand how people living with diabetes can stay more actively involved in their health Lilly has been a leader in diabetes care for more than 90 years, and was the first company to make insulin commercially available to people with the disease. Today, Lilly provides a wide range of therapies to address the diverse needs of people living with diabetes. Collaborating with Livongo is an important step in our research efforts, said Sherry Martin, MD, vice president of Medical Affairs, Lilly Diabetes.We hope that our combined expertise will play a key role in empowering people with diabetes to better manage their condition. Livongo is redesigning chronic condition management, starting with diabetes. Livongo delivers a personalized experience, using data and clinical science, and helps to make staying healthy easier, which results in measurable positive health outcomes for people with diabete Continue reading >>

Eli Lilly's Deal With Diabetic Nascar Driver Could Help It Regain Market Share

Eli Lilly's Deal With Diabetic Nascar Driver Could Help It Regain Market Share

Eli Lilly's Deal With Diabetic NASCAR Driver Could Help It Regain Market Share OUR TERMS OF SERVICE AND PRIVACY POLICY HAVE CHANGED Eli Lilly's Deal With Diabetic NASCAR Driver Could Help It Regain Market Share Eli Lilly's approximately $10M annual investment in and around NASCAR Xfinity Series driver Ryan Reed "is a drop in the bucket" for the Indianapolis-based pharmaceutical brand, "but could be critical to boosting the companys market share in a field it once dominated," according to Anthony Schoettle of the INDIANAPOLIS BUSINESS JOURNAL. Though it is partnering with the American Diabetes Association, ADA officials said that Lilly is "footing the bill -- which sources close to the deal pegged" at $5Mannually. Sources said thatLilly "will spend as much to activate andpromote its sponsorship -- through activities at NASCAR tracks beforeand during races and hospital visits featuring Reed in NASCAR markets --as it spends on the deal itself." Reed, who has Type 1 diabetes, won the season-opening Xfinity Series race, but the win "was only the start of his impressive Daytona performance." Reed during his post-race interview said, "This is for ... every kid who gets diagnosed with diabetes, or anything that says you cant do something." American Diabetes Association Managing Dir of Corporate Alliances & Cause-Related Marketing Steve Wosahla: "It was amazing that, in the heat of the moment, that he was so spot-on with his messaging. Thats more than you could expect from a seasoned (marketing) professional." Though the partnership "might now seem like a no-brainer, Wosahla said Lilly wasnt the only maker of diabetes medications the ADA contacted about sponsoring Reed." Lilly originally "wasnt looking to get into racing," as it "had only one stint in racing -- open-wheel racin Continue reading >>

Trump’s Pick To Lower Drug Prices Is A Former Pharma Executive Who Raised Them

Trump’s Pick To Lower Drug Prices Is A Former Pharma Executive Who Raised Them

President Trump's pick for health secretary previously served as a high-ranking executive at a pharmaceutical company that repeatedly raised the prices of its drugs, doubling the U.S. list price of its top-selling insulin over the five years he served as a company president. Trump endorsed Alex Azar, a previous deputy secretary of Health and Human Services under President George W. Bush and pharmaceuticals executive at diabetes pharmaceuticals giant Eli Lilly, as “a star for better health care and lower drug prices” on Twitter. Supporters said that Azar's understanding of the complicated dynamics behind pharmaceuticals pricing would give him an advantage in figuring out how to make drugs more affordable. Critics, however, noted that Azar's tenure at Lilly coincided with massive list price increases on insulin and made him particularly ill-suited to lower drug prices. While Azar led Eli Lilly's largest affiliate, Lilly USA, the U.S. list price of Humalog insulin more than doubled, from $123 per vial in Jan. 2012 to $255 per vial when he left the company in early 2017, according to data from Truven Health Analytics. Lilly, along with other insulin makers, was hit by a class-action lawsuit alleging overpricing of insulin earlier this year. “Alex had a successful career at Lilly, and we wish him the best in his future work,” Lilly spokesman Greg Kueterman said in an email. Azar joined Lilly in 2007 as a senior vice president of global corporate affairs and communications. He rose to become president of the company's largest affiliate, Lilly USA, in 2012. Kueterman said his responsibilities included direction over the sales and marketing operations of the entire U.S. commercial business, including diabetes. “This is the terrible record on price that we saw; now we Continue reading >>

American Diabetes Association: 2018 Tour De Cure: Jax

American Diabetes Association: 2018 Tour De Cure: Jax

The Tour de Cure is an event where no matter what road you take, you will be joining thousands of people from around the country who have the same passion as you to fight diabetes and its burdens. All riders, runners and walkers will be treated to lunch and a fantastic celebration party for all to enjoy. The Tour de Cure is bigger and better than ever with options for everyone. Cycling will make you feel the power of the pedal as you join the fight to end diabetes. The Tour de Cure's cycling routes are for people of all cycling abilities and is regarded as one of the top multi-site cycling events in the country. The routes are well-marked, there are safety marshals and safety vehicles, fully stocked rest stops and more. Running shows not only physical determination but the determination to end diabetes. The Tour de Cure is now open to all runners! If you choose to run you will receive a timing chip and will run on a beautiful 5k route. What a great way to celebrate health, fitness and fun! Walking together with family, friends and coworkers shows your community you want a cure. Walking is a great way to get out and get healthy all while celebrating those living with diabetes. You will be among hundreds of walkers who share your passion as you walk along a beautiful route. After registering you will have access to your participant center which is your fundraising hub. You will have a personal page to share your story, mobile apps, email templates and more.Once you set your goal Elizabeth or Kara will help you every step of the way so you can achieve it.Fundraising has never been easier; and be sure to check out our 2018 Recognition Gifts for some additional inspiration! And be sure to visit our new Toolkit Page where you can find lots of helpful fundraising resources at Continue reading >>

Welcome | Efsd

Welcome | Efsd

Applicants to all EFSD programmes must be paid-up members of EASD. Access MyEASD to apply for EASD membership or to manage your account. For further information, please see here or contact [email protected] . Applicants toEFSD collaborative programmeswith non-European countries are exempt from this regulation. Information for potential grant applicants EFSD continuously strives to offer funding streams that are well suited to todays research needs and that attract the very best grant applications to move the field forward. This brochureis designed to encourage you to apply for funding and to help you put together the best possible application:we hope you will find it interesting and helpful! Simply click on the document on the left to start reading and watching or download here and save to your device to capture the embedded videos. The European Association for the Study of Diabetes e.V. (EASD) is a non-profit, medical scientific association and was founded in 1965. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. more Diabetologia is the Journal of the EASD and publishes original clinical, translational and experimental research within the field of diabetes. We are interested in papers that convey new information or insight into any aspect of the condition, ranging from basic science to clinical applications. more Register now for the 54th EASD Annual Meeting! #EASD2018 will be full of exciting insights into the most recent research findings in all aspects of #diabetology. #EASD2018 #diabetes #research #T1D #T2D #Berlin - pic.twitter.com/fq0LTCK3G6 Continue reading >>

Indianapolis Motor Speedway

Indianapolis Motor Speedway

103rd Running of the Indianapolis 500 Thirty-three drivers. 200 laps. 500 miles. One bottle of cold milk. The only thing missing from this magical Indianapolis 500 mix is you. Don't miss out on another incredible edition of "The Greatest Spectacle in Racing." Learn More Buy Tickets Bloomington Gold Bloomington Gold Corvettes is the longest-running all-Corvette event in the country and is attended by more than 30,000 people each year. Bloomington Gold is recognized worldwide among car owners for its prestigious judging process of Corvettes and the authentication a Bloomington Gold Certification brings to a Corvette. Learn More Buy Tickets LPGA Indy Women in Tech Championship The Ladies Professional Golf Association (LPGA) will host the Indy Women in Tech Championship presented by Guggenheim. The tournament will feature a full field of 144 players competing for a $2 million purse. Learn More Buy Tickets Big Machine Vodka 400 at the Brickyard powered by Florida Georgia Line The 25th annual Big Machine Vodka 400 at the Brickyard powered by Florida Georgia Line moves to a new date in 2018, scheduled for Sunday, Sept. 9. Learn More Buy Tickets Red Bull Air Race The Red Bull Air Race returns to the Indianapolis Motor Speedway Oct. 6-7. Experience full-throttle aerial racing on a unique course inside the iconic IMS oval designed to push the best pilots in the world to their limits. Learn More Buy Tickets INDYCAR Grand Prix Get closer to the action at the INDYCAR Grand Prix as the stars of the Verizon IndyCar Series take on the twists and turns of the IMS road course. This family-friendly event includes driver autograph sessions and the chance to walk on the legendary Yard of Bricks during the post-race track invasion! Renew your tickets now for the 2019 INDYCAR Grand Prix! Lea Continue reading >>

Lilly Diabetes Executive Becomes Cmo At Mannkind

Lilly Diabetes Executive Becomes Cmo At Mannkind

Lilly diabetes executive becomes CMO at MannKind MannKind, whose inhaled insulin Afrezza has yet to make much impression in the market, has now got a former Lilly diabetes executive onboard to help it. MannKind, which continues to try to convince the market of the value of its inhaled insulin, has enticed a top scientific executive away from Eli Lilly as it explores new areas for the fast-acting drug. The WestlakeVillage, California-based company Tuesday announced thatDavid Kendall, M.D., has joined as MannKinds chief medical officer. Beginning next week, he takes on responsibility for leading MannKinds scientific research, clinical development, regulatory, and medical affairs activity. Like this story? Subscribe to FiercePharma! Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go. David is a world-renowned diabetes expert and represents an important addition to our executive leadership team, MannKind CEO Michael Castagna said in a statement. His extensive experience in diabetes research, developmentand clinical care in both U.S. and international marketswill be instrumental in helping us achieve the growth potential that we believe Afrezza clearly possesses. Kendall most recently was theresearch physician and vice president of global medical affairs for Lilly Diabetes. A Lilly spokesman said: "Were thankful for everything David did during his seven years at Lilly, and we wish him the best in his new role." Kendall takes the spot vacated in September byRaymond W. Urbanski, M.D., who left MannKind to work in oncology. Kendall Continue reading >>

Bernie Sanders' Tweets Send Lilly Shares Tumbling

Bernie Sanders' Tweets Send Lilly Shares Tumbling

Bernie Sanders' tweets send Lilly shares tumbling Sanders criticized Lilly's pricing for a form of insulin. Bernie Sanders' tweets send Lilly shares tumbling Sanders criticized Lilly's pricing for a form of insulin. Check out this story on IndyStar.com: A link has been sent to your friend's email address. A link has been posted to your Facebook feed. Bernie Sanders' tweets send Lilly shares tumbling James Briggs , [email protected] Published 2:44 p.m. ET Nov. 1, 2016 | Updated 10:46 p.m. ET Nov. 1, 2016 A series of critical tweets from Sen. Bernie Sanders sent shares of Eli Lilly and Co. tumbling Tuesday, Nov. 1, 2016. A series of social media posts from U.S. Sen. Bernie Sanders on Tuesdaysent shares of Eli Lilly and Co. briefly tumbling to a seven-month low. Sanders' Twitter account posted alink to a Washington Post article detailing the decadeslong price increase of a Lillyinsulin called Humalog. The price of Humalog has risen from $21 a vial to more than $250 during the past 20 years, according to The Post. The tweets went out to Sanders' 2.7 million Twitter followers. They were not signed by Sanders, indicating they werewritten by members of his staff. After sharing The Post's article, Sanders' account posted several other messages that weresharply critical of the Indianapolis drugmaker. "Why has the price of Humalog insulin gone up 700% in 20 years?" one post read ."It's simple. The drug industry's greed." Eli Lilly and Novo Nordisk clearly care more about their profits than their patients. It's time to end their greed. pic.twitter.com/MqCsHNjzcO Bernie Sanders (@SenSanders) November 1, 2016 Humalog is a fast-acting insulin used to control blood sugar for people with diabetes. As Sanders' Twitter account blasted Lilly, the company's stock price fell by as Continue reading >>

Advance Preparation Is A Key Defense For Chronic Disease Management During Emergencies.

Advance Preparation Is A Key Defense For Chronic Disease Management During Emergencies.

Advance preparation is a key defense for chronic disease management during emergencies. When youre dealing with a chronic medical condition like diabetes, diligence and preparation are key. But when an emergency situation or natural disaster strikes at your home or workplace whether fires or floods, hurricanes, blizzards or even something like an unexpected auto breakdown the disruption of a normal routine and limited access to much-needed resources can create chaos. Being caught unprepared for these types of events can be potentially life-threatening to a person with diabetes. Thats why the American College of Endocrinology (ACE) created the My Diabetes Emergency Plan. Launched by ACE in 2006, in response to the aftermath of Hurricane Katrina, the My Diabetes Emergency Plan is a convenient checklist that contains all of the essential items those with diabetes need to have readily available in the event of an emergency. On this site, you can download the plan in English or Spanish and view a step-by-step video demonstration of how to put your kit together. We also offer helpful resources for emergency preparedness officials, *first responders* and healthcare personnel to communicate with community members and patients for whom you care. American Association of Clinical Endocrinologists Continue reading >>

Eli Lilly Bets Big On Insulin-delivery Devices

Eli Lilly Bets Big On Insulin-delivery Devices

CAMBRIDGE, Mass.—Eli Lilly & Co., one of the biggest makers of insulin, has been planning a risky new business venture: making the high-tech devices that deliver insulin to diabetes patients. In a research laboratory Lilly opened here in 2015, scientists have been developing a wearable, automated insulin-delivery device designed to reduce the decision-making and guesswork of conventional insulin injections. They are also developing a “smart pen” injection device that can wirelessly transmit dosing information to a patient’s phone, to ensure proper dosing. Lilly’s previously undisclosed projects, for which the company has enlisted several design and device-firm partners, including the inventor of the Segway scooter, is an unusual example of diversification at a time when much of the drug industry is moving in the opposite direction—shedding nondrug businesses to focus on pharmaceuticals. Indianapolis-based Lilly, the first company to mass produce insulin in 1923, faces competitive pressures including the expected arrival of lower-cost copies of its top-selling insulin, Humalog. And it sees growth in the market for advanced insulin-delivery devices. Enrique Conterno, head of Lilly’s diabetes business, said he believed Lilly’s insulin business would become “obsolete” if the company remained largely an insulin provider without delivery systems. “Do we want to be just an insulin provider that just goes into a system, or do we want to be the integrator of the system?” he said at the Cambridge lab this month. “To me, it’s clear where the business is going.” ​Lilly’s insulin products currently generate about 20% of the company’s total revenue. Still, the projects are a risky bet because Lilly will compete with medical-device heavyweights like Continue reading >>

Lilly Diabetes To Co-sponsor Conor Daly Of Dale Coyne Racing In 100th Running Of The Indianapolis500

Lilly Diabetes To Co-sponsor Conor Daly Of Dale Coyne Racing In 100th Running Of The Indianapolis500

Lilly Diabetes to Co-Sponsor Conor Daly of Dale Coyne Racing in 100th Running of the Indianapolis500 Dale Coyne Racing and Conor Daly team up with Lilly Diabetes to bring awareness to the number of military veterans living with diabetes One in four veterans are living with diabetes, which is more than the general population Plainfield, IL (May 26, 2016) Dale Coyne Racing today announced that Lilly Diabetes of Indianapolis-based Eli Lilly and Company (LLY) will serve as co-primary sponsor of the No. 18 ShirtsForAmerica.com/Lilly Diabetes Honda, driven by Conor Daly, in the 100th Running of the Indianapolis 500 on Sunday, May 29. As part of the sponsorship, Dalys No. 18 car will run a special patriotic paint scheme with a series of four stars, one colored in blue to recognize the one in four veterans who live with diabetes, which is two and a half times greater than the general population. In 2006, at age 14 Daly was diagnosed with Type 1 diabetes. Now 24, Daly continues to manage his diabetes through proper diet, exercise, and medicines. The Noblesville, Ind., native wears a glucose monitoring system to help manage his diabetes and his No. 18 Honda is equipped with a glucose monitoring readout device. We are proud to partner with Lilly Diabetes for the Indianapolis 500 to help bring awareness to the number of veterans living with diabetes and help connect fans with Lilly as a resource for proper management of diabetes, said Team Owner, Dale Coyne. With the Memorial Day weekend and the sponsors we have on Conors car, we couldnt be more excited about Sundays race. Lilly, a leader in diabetes care for more than 93 years, has been providing solutions and support for people affected by diabetes since 1923 when the company introduced the worlds first commercialized insulin. M Continue reading >>

Life With Type1 Diabetes Made A Little Easier Through Lilly Diabetes Scholarship

Life With Type1 Diabetes Made A Little Easier Through Lilly Diabetes Scholarship

Why do kids love diabetes camp? See for yourself! Click here to watch Nashville recording artist and Lilly Diabetes Ambassador Crystal Bowersox share her story at her hometown diabetes camp. Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences Lilly scholarship donations total more than $1.3 million since 2008 INDIANAPOLIS, ARLINGTON, Va., and ROLLING MEADOWS, Ill. (April 7, 2017) Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical and emotional worries can be overwhelming. To help support people with diabetes and those who love them, Lilly Diabetes today announced it will donate $94,000 to the American Diabetes Association (Association) Campership program and $100,000 to the Diabetes Scholars Foundation (Foundation). Both donations are part of Lillys longstanding commitment to give people with diabetes access to education, community and inspiration. The Association conducts nearly 70 camp sessions annually throughout the U.S. to help children with type 1 diabetes develop skills to independently manage their diabetes through traditional camp activities, medical support and fun. Attending camp can instill confidence and help children understand they are not alone. In fact, a three-year survey conducted by the Association found that attending camp increased confidence and lowered diabetes-related stress in some campers.1 Lilly Diabetes $94,000 donation goes directly to the Associations Campership program, which awards scholarships based on financial need. The amount represents $1,000 for each year Lilly has supported those living with diabetes since introducing the worlds first commercial insulin in 1923 Continue reading >>

More in diabetes